Belimumab is a fully human monoclonal antibody targeting B-cell Activating Factor (BAFF) and is licensed for the treatment of Systemic Lupus Erythematous (SLE) (118). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.